

PROPOSED AMENDMENTS TO HOUSE BILL NO. 1455

- Page 1, line 4, after the first "biotechnology" insert "in the health care industry"
- Page 1, line 4, after "products" insert "for use in the health care industry"
- Page 1, line 10, after the first "**biotechnology**" insert "**in the health care industry**"
- Page 1, line 11, after "**products**" insert "**used in the health care industry**"
- Page 1, line 14, after "biotechnology" insert "in the health care industry"
- Page 1, line 15, after "manufacturing" insert "in the health care industry"
- Page 2, line 6, after "products" insert "in the health care industry"
- Page 2, line 8, replace "in areas" with "in the health care industry"
- Page 2, line 10, after the third underscored comma insert "and"
- Page 2, line 10, remove ", veterinary medicine."
- Page 2, remove line 11
- Page 2, line 12, remove "security applications of bioscience"
- Page 2, line 14, after "technologies" insert "for use in the health care industry"
- Page 2, line 19, remove "or animal"
- Page 2, line 24, after "state" insert "and research conducted for purposes unrelated to the health care industry"
- Page 2, line 25, remove "capital equipment, instruments, apparatus."
- Page 2, line 26, remove "inputs, and"
- Page 2, line 29, after "bioscience" insert "in the health care industry"
- Page 2, line 31, after "processes" insert "in the health care industry"
- Page 3, line 4, after "biotechnology" insert "in the health care industry"
- Page 3, line 5, after "manufacturing" insert "in the health care industry"
- Re-number accordingly

HOUSE BILL NO. 1455

Introduced by

Representatives O'Brien, Hagert, Monson, Roers Jones, Schauer, Schreiber-Beck
Senators Kreun, Patten, J. Roers, Wanzek

1 A BILL for an Act to create and enact a new section to chapter 57-39.2 and a new subdivision to
2 subsection 4 of section 57-40.2-03.3 of the North Dakota Century Code, relating to a sales and
3 use tax exemption for materials used in the research and development of bioscience and
4 biotechnology in the health care industry and manufacture of bioscience and biotechnology
5 products for use in the health care industry; and to provide an effective date.

6 **BE IT ENACTED BY THE LEGISLATIVE ASSEMBLY OF NORTH DAKOTA:**

7 **SECTION 1.** A new section to chapter 57-39.2 of the North Dakota Century Code is created
8 and enacted as follows:

9 **Sales tax exemption for materials used in the research and development of**
10 **bioscience and biotechnology in the health care industry and manufacture of bioscience**
11 **and biotechnology products used in the health care industry.**

- 12 1. Gross receipts from sales of tangible personal property purchased for use, storage, or
13 consumption directly and predominately in the research and development of
14 bioscience and biotechnology in the health care industry and raw materials or
15 consumables purchased for use, storage, or consumption which are critical to biologic
16 manufacturing in the health care industry.
- 17 2. To receive the exemption at the time of purchase, the qualified biotechnology taxpayer
18 or qualified bioscience taxpayer must receive from the tax commissioner a certificate
19 that the tangible personal property, raw materials, or consumables qualify for the
20 exemption. If a certificate is not received before the purchase, the qualified
21 biotechnology taxpayer or qualified bioscience taxpayer shall pay the applicable tax
22 imposed by this chapter and apply to the tax commissioner for a refund.
- 23 3. If the tangible personal property, raw materials, or consumables are purchased or
24 installed by a contractor subject to the tax imposed by this chapter, the qualified

- 1 biotechnology taxpayer or qualified bioscience taxpayer may apply for a refund of the
2 difference between the amount remitted by the contractor.
- 3 4. For purposes of this section:
- 4 a. "Biologic manufacturing" includes the manufacturing process used to support
5 biologic product generation, product impurity removal, chemical or physical
6 product alteration, and analysis of in-process to final deliverable products in the
7 health care industry.
- 8 b. "Bioscience" means the use of compositions, methods, and organisms in cellular
9 and molecular research, development, and manufacturing processes in areas in
10 the health care industry, including pharmaceuticals, medical therapeutics,
11 medical diagnostics, medical devices, medical instruments, biochemistry, and
12 microbiology, ~~veterinary medicine, plant biology, and agriculture and industrial,~~
13 ~~environmental, and homeland security applications of bioscience.~~
- 14 c. "Biotechnology" means:
- 15 (1) The application of technologies for use in the health care industry to
16 produce or modify products, to develop micro-organisms for specific uses,
17 to identify targets for small pharmaceutical development, or to transform
18 biological systems into useful processes or products; and
- 19 (2) The potential endpoints of the resulting products, processes,
20 micro-organisms, or targets for improving human ~~or animal~~ health care
21 outcomes.
- 22 d. "Raw materials" include chemicals, nutrients, reagents, and biologic catalysis.
- 23 e. "Research and development" means qualified research as defined in section
24 41(d)(1) of the Internal Revenue Code [26 U.S.C. 41(d)(1)], except it does not
25 include research conducted outside the state and research conducted for
26 purposes unrelated to the health care industry.
- 27 f. "Tangible personal property" includes ~~capital equipment, instruments, apparatus,~~
28 ~~inputs, and~~ supplies used in laboratories, including microscopes, machines,
29 glassware, computers, computer software, and technical books and manuals.
- 30 g. "Qualified bioscience taxpayer" means a person that is engaged in the business
31 of bioscience in the health care industry in the state and has business operations

1 in the state, including research, development, or production directed toward
2 developing or providing bioscience products or processes in the health care
3 industry for specific commercial or public purposes.

4 h. "Qualified biotechnology taxpayer" means a C corporation, partnership, limited
5 liability company that is not a C corporation, S corporation, or sole proprietorship
6 that purchases, stores, uses, or consumes tangible personal property to be used
7 directly and predominately in the research and development of biotechnology in
8 the health care industry or raw materials or consumables that are critical to
9 biologic manufacturing in the health care industry.

10 **SECTION 2.** A new subdivision to subsection 4 of section 57-40.2-03.3 of the North Dakota
11 Century Code is created and enacted as follows:

12 Tangible personal property, raw materials, or consumables as authorized or
13 approved for exemption by the tax commissioner under section 1 of this Act.

14 **SECTION 3. EFFECTIVE DATE.** This Act is effective for taxable events occurring after
15 June 30, 2023.

